Other languages BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Real-time Estimate Cboe BZX Other stock markets 11:09:11 2024-06-06 am EDT			5-day change	1st Jan Change
79.74 ^USD	+0.09%		+6.86%	-17.45%

May. 31	BioMarin Pharmaceutical Insider Sold Shares Worth $3,043,802, According to a Recent SEC Filing	MT
May. 17	Baird Downgrades BioMarin Pharmaceutical to Neutral From Outperform, Cuts Price Target to $72 From $104	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioMarin Pharmaceutical Insider Sold Shares Worth $3,043,802, According to a Recent SEC Filing	May. 31
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing	May. 13
Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing	May. 06
Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04
BioMarin Pharmaceutical Inc. Announces That Positive New Data Supporting the Safety and Efficacy of VOXZOGO® in Children	May. 04
RACCOMANDAZIONI DEGLI ANALISTI USA/UK : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Alphabet, Amgen, Starbucks, PayPal, Moderna...	May. 03
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says	Apr. 29
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours	Apr. 24
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24
Biomarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024	Apr. 24
Biomarin Pharmaceutical Insider Sold Shares Worth $3,645,000, According to a Recent SEC Filing	Apr. 15
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	Apr. 01
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia	Mar. 12
ETF der Woche: Auf die Wende der Biotechs setzen	Mar. 10
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech	Mar. 09
ETF van de week: inzetten op de ommekeer in de biotech	Mar. 08
ETF de la semaine : miser sur le retournement des Biotechs	Mar. 08
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing	Mar. 07
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer	Mar. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Other languages

Filters